EGFR and non-small cell lung carcinoma: Subsequent phase III trials have demonstrated the superiority of combining first-generation EGFR-TKIs with antiangiogenic agents over monotherapy in improving progression-free survival for patients with advanced NSCLC harboring EGFR mutations [55–63].